GlobeNewsWire · SNDX · October 12, 2026

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Get the app for more

Explore stock news, insights and company research.